Staff Profile

I am a Research Fellow of the Edmond J Safra Accelerating clinical trials in Parkinson's disease (EJS ACT-PD) initiative where I have supported efforts to scope and improve PD clinical research infrastructure as well as develop and evaluate patient and public involvement and engagement (PPIE).

I have a background in molecular biology with four years of experience in researching cannabinoids as neuroprotective agents in a cell culture model of Parkinson’s disease and more than 9 years of experience in laboratory-based research with hands-on experience in a wide variety of laboratory research techniques. 

I am a fellow of the ACORD collaboration.

I have a passion for actively incorporating the patient voice in research. Together with the EJS ACT-PD PPIE group, which consists of 13 patients and are partners, I have co-developed, put into practice and evaluated mechanisms that allow the effective training and engagement of patients and carers in the development of the EJS ACT-PD trial. I have conducted a study to assess the impact of patient and carer involvement in the EJS ACT-PD initiative.

I am involved in the development of trial delivery models that anticipate workforce and recruitment needs for the EJS ACT-PD trial as well as developing strategies to actively encourage the engagement with minority and underserved groups.

Together with Prof Camille Carroll and Prof Yan Yiannakou, I have been developing a national research register for people with Parkinson's called Join Parkinson's Research hosted by Research+Me (JPR@Research+Me).

• Articles

  • Zeissler M-L, Bakshi N, Bartlett M, Batla A, Byrom D, Chapman R, Collins S, Cowd E, Deeson E, Ellis-Doyle R, Forbes J, Gonzalez-Robles C, Jewell A, Lane EL, LaPelle NR, Martin K, Matthews H, Miller L, Mills G, Morgan A, Parry M, Pushparatnam K, Ratcliffe N, Salathiel D, Scurfield P, Siu C, Whipps S, Wonnacott S, Foltynie T, Carroll CB, McFarthing K. Patient and Public Involvement and Engagement in the Development of a Platform Clinical Trial for Parkinson's Disease: An Evaluation Protocol. Journal of Parkinson's Disease 2024, 14(4), 809-821.
  • Gonzalez-Robles C, Weil RS, Van Wamelen D, Bartlett M, Burnell M, Clarke CS, Hu MT, Huxford B, Jha A, Lambert C, Lawton M, Mills G, Noyce A, Piccini P, Pushparatnam K, Rochester L, Siu C, Williams-Gray CH, Zeissler M-L, Zetterberg H, Carroll CB, Foltynie T, Schrag A. Outcome Measures for Disease-Modifying Trials in Parkinson's Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative. Journal of Parkinson's Disease 2023, 13(6), 1013-1035.
  • Zeissler M-L, Boey T, Chapman D, Rafaloff G, Dominey T, Raphael KG, Buff S, Pai HV, King E, Sharpe P, O'Brien F, Carroll CB. Investigating trial design variability in trials of disease-modifying therapies in Parkinson’s disease: a scoping review protocol. BMJ Open 2023, 13(12), e071641.

• Review

  • Foltynie T, Gandhi S, Gonzalez-Robles C, Zeissler M-L, Mills G, Barker R, Carpenter J, Schrag A, Schapira A, Bandmann O, Mullin S, Duffen J, McFarthing K, Chataway J, Parmar M, Carroll C, Shlomo YB, Edwards M, Whone A, Counsell C, Clarke C, Burnell M, Salathiel D, Whipps S, Jewell A, Barber T, Weil R, Gray CW, Hu M, Rochester L, Piccini P, Zetterberg H, Noyce A, Chaudhuri R, Lawton M, Jha A, Siu C, Bartlett M, van Wamelen D, Stott S, Tofaris G, Sammler E, Mortiboys H, Wei L, Wong A, Duty S, Dexter D, Scurfield P, Jabbari E, Morris H, Breen D, Lambert C, Korlipara P, Silverdale M, Bhatia K, Yarnall A, Khengar R, Collins H, Hudson F, Baxendale G, Croucher R, Bartolomeur-Pires S, Allison J, Morgan A, Wonnacott S, Athauda D, Henderson E, Clegg S, Matthews K, Deeson E, Miller L, Handley J, Matthews H, Batla A, Bakshi N, Port B, Ellis-Doyle R, Collins SL, Rudiger J, Chapman R, Cedarbaum J, Lang A, Fiske B, Wyse R, Boxer A, Wilson D, Corvol JC, Harris J. Towards a multi-arm multi-stage platform trial of disease modifying approaches in Parkinson’s disease. Brain 2023, 146(7), 2717-2722.